利妥昔单抗为基础方案治疗再生障碍性贫血单倍体移植后儿童EB病毒相关淋巴细胞增殖性疾病:一项前瞻性单中心研究
本研究纳入31例再生障碍性贫血患儿行单倍体造血干细胞移植后发生EB病毒相关移植后淋巴细胞增殖性疾病(PTLD)的病例,按单次利妥昔单抗治疗后是否下降1个log分为利妥昔单抗单药组或联合治疗组。AA患儿移植后PTLD发生率为10.16%,年龄>10岁者发生率明显升高(χ²=11.336,P=0.010)。27例治愈,3例死亡,2年总生存率为(89.7±5.6)%;标准预处理方案和EBV复阳是影响预后的危险因素,两种治疗方案对预后影响差异无统计学意义。
要点
- AA患儿单倍体移植后PTLD发生率为10.16%,年龄>10岁者发生率明显升高(χ²=11.336,P=0.010)。
- 31例中临床诊断27例、病理确诊4例;利妥昔单抗单药组15例、联合治疗组15例,27例治愈、3例死亡。
- 2年总生存率为(89.7±5.6)%;标准预处理方案和EBV复阳是影响PTLD预后的危险因素。
核心结论
- AA患儿单倍体移植后PTLD发生率为10.16%,2年总生存率为(89.7±5.6)%。
- 标准预处理方案和EBV复阳是影响PTLD预后的危险因素。
- 两种治疗方案对预后影响差异无统计学意义。
研究设计与样本
- 前瞻性单中心研究,纳入31例再生障碍性贫血行单倍体移植后发生PTLD的病例。
- 按利妥昔单抗治疗1次后是否能下降1个log分为利妥昔单抗单药治疗组或联合治疗组。
主要发现
- AA患儿移植后PTLD发生率为10.16%,年龄>10岁者PTLD发生率明显升高(χ²=11.336,P=0.010)。
- 31例患者中临床诊断27例,病理确诊4例。
- 利妥昔单抗单药治疗组15例,联合治疗组15例;最终27例患儿治愈,3例患儿死亡。
- 2年总生存率为(89.7±5.6)%。
- 标准预处理方案、EBV复阳是影响PTLD预后的危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) are one of the most severe complications after hematopoietic stem cell transplantation (HSCT). This study includes 31 cases of aplastic anemia (AA) patients who developed PTLD after haploidentical transplantation, summarizing their clinical characteristics and categorizing them into either rituximab monotherapy group or combination therapy group based on whether their condition improved by 1 log after a single dose of rituximab. The incidence of PTLD after HSCT in children with AA was 10.16%, and the incidence of PTLD in patients with age >10 years was significantly increased (χ(2)=11.336, P=0.010). Of the 31 patients, 27 were clinically diagnosed and 4 were pathologically confirmed. Finally, 15 patients were classified into the rituximab treatment group and 15 patients into the combination treatment groups. Finally three patients died, and the 2-year overall survival rate was (89.7±5.6) %. Standard pre-treatment protocols and EBV reactivation are risk factors affecting the prognosis of PTLD. There was no statistically significant difference in the impact of the two treatment schemes on prognosis. EB病毒(EBV)相关移植后淋巴细胞增殖性疾病(PTLD)是造血干细胞移植后最严重并发症之一。本研究纳入31例再生障碍性贫血(AA)行单倍体移植后发生PTLD的病例,归纳其临床特点,并按照利妥昔单抗治疗1次后是否能下降1个log分为利妥昔单抗单药治疗组或联合治疗组。AA患儿移植后PTLD发生率为10.16%,年龄>10岁者PTLD发生率明显升高(χ(2)=11.336,P=0.010)。31例患者中临床诊断27例,病理确诊4例。利妥昔单抗单药治疗组15例,联合治疗组15例。最终27例患儿治愈。3例患儿死亡,2年总生存率为(89.7±5.6)%。标准预处理方案、EBV复阳是影响PTLD预后的危险因素。两种治疗方案对预后影响差异无统计学意义。.
引用
- Zhang F, Hu GH, Suo P, et al. [Rituximab based treatment in pediatric Epsstain Bar Virus associated lymphocyte proliferative diseases after aplastic anemia with haplo-identical transplantation:a prospective single centre study]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39231773. doi:10.3760/cma.j.cn121090-20231229-00345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。